63 results about "Prevention of diabetes mellitus type 2" patented technology

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

A composition for the treatment, prevention or management of a condition in primates, especially humans comprising a phenolic antioxidant-chromium complex.

Substituted cyclopropyl compounds of formula (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

The invention relates to lactobacillus rhamnosus CCFM0528 having an inhibitory effect on alpha-glucosidase activity, the bacterial strain is preserved at the China General Microbiological Culture Collection Center (CGMCC), and the accession number is CGMCC No.7317. Cytoplasm and fermentation supernate of the CCFM0528 can respectively exhibit the inhibitory effects on the alpha-glucosidase activity, with the inhibition rates of 29.2% and 14.1% respectively. Studies show that the CCFM0528 exhibits the inhibitory effect not only on the alpha-glucosidase activity, also on glucose transport. The experimental results show that the CCFM0528 can prevent type-2 diabetes, effectively reduce fasting blood glucose and postprandial blood glucose of mice, and improve glucose tolerance of the mice. The principle may be that the CCFM0528 has inhibitory effect on the alpha-glucosidase activity and enzyme expression amount in intestinal tract, and can influence the gene expression level of glucose-transport relating protein SGLT-1 and GLUT-2.

The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

The invention relates to the field of natural medicaments, in particular to a cassia bark polyphenol extract and a preparation method and application thereof. The preparation method is characterized by comprising the following steps of: removing fat soluble substances from cassia bark by using CO2 supercritical extraction, extracting extraction residues by water or a water mixed solvent to obtaina cassia bark polyphenol coarse extract of which the content of total phenol is about 6 percent, and purifying by using SP207 macroporous adsorbent resin to obtain the cassia bark polyphenol extract,wherein the content of total polyphenol is over 26 percent, the purity is high, and the quality is stable. In the cassia bark polyphenol extract, cassia bark polyphenol has the effects of reducing blood sugar, regulating blood fat and improving liver functions in the treatment and prevention of type 2 diabetes.

The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.

Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R¹, R², R³, R⁴, R⁵, X, Alk¹, Alk², Ar¹, and Ar² are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.

The invention discloses an anemarrhenae extract and the application as a medicine treating type II diabetes thereof. The invention uses membrane separation technology, macropore to absorb resin separation and refines anemarrhenae extract after extracting the hizome anemarrhenae by water and ethanol with water. The main activities of the anemarrhenae extract of the invention are three kinds or any two kinds among anemarrhenae saponins, anemarrhenae polysaccharides and double benzene pyrrole ketones, and the total content of the main active components is up to more than 50 percent. The pharmacological experiment of the anemarrhenae extract of the invention proves that the medicine has a big medical value and economic benefit as the medicine for treating or preventing type II diabetes and the complications thereof.

Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus.

The invention provides application of a ferric iron ferriporphyrin compound in preparation of an anti-type-2 diabetes drug and belongs to the technical field of biological pharmacy. The ferric iron ferriporphyrin compound consists of heme and oligopeptide. A carboxyl of the heme is connected with an amino on a peptide chain through an amido bond to achieve connection of the heme and the oligopeptide. Other type-2 diabetes treating or preventing drugs can be applied to the drug preparation. The ferric iron ferriporphyrin compound serves as a peroxidase stimulant, has small molecular weight, can enter cells to effectively remove internal superoxide, super-oxygen ions and free radicals and has the effects of reducing blood sugar, cholesterol and triglycerides activity.

This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.

The invention discloses a health food for prevention of type 2 diabetes and a preparation method thereof, relates to the field of natural green food. The health food is mainly composed of a luffa seed powder, a food additive, and optionally a grain powder, a fruit juice or tea. The luffa powder is prepared by the following method: taking luffa seeds, washing the seeds, placing the seeds in an oven, baking for 12-18 h at 20-50 DEG C to obtain dried luffa seeds; hulling the luffa seeds, and grinding the seeds into a powder; and sieving the powder through a 100 mesh to obtain the luffa powder. The invention develops the health food with luffa seeds as the raw material for prevention of type 2 diabetes, and aims at glucose tolerant patients, the group with strong genetic background of type 2 diabetes, the group with irregular daily schedule and the obese.

Methods and compositions for treating or preventing type 2 diabetes by inhibiting expression or activity of monoacylglycerol O-acyltransferase 1 (MOGAT1) are disclosed. Also disclosed are methods to identify such compositions.

The present invention provides the use of brown algae-derived glucuronic acid-rich low-sulfated heteroglycan in the preparation of medicaments or health products for the treatment and/or prevention oftype 2 diabetes. The low-sulfated heteroglycan has the following characteristics: the monosaccharide component mainly comprises fucose and glucuronic acid, and further comprises one or more of mannose, glucose, rhamnose, galactose, xylose, guluronic acid and mannuronic acid; wherein the content of the hydrolyzed sulfate group is 5 to 28 percent, the content of the fucose is 3 to 28 percent and the content of the uronic acid is 5 to 30 percent. The heteroglycan has stronger effect on promoting glucose consumption in HepG2 cells than fucoidan sulfate fraction, and it has obvious effect on enhancing insulin secretion in islet beta cells.